Purpose: The activity and toxicity of paclitaxel plus carboplatin combination in patients with disease progression after initial chemotherapy for small-celt lung cancer (SCLC) was investigated in a multicenter phase II study.
Introduction
Small-cell lung cancer (SCLC) represents 20%-25% of all the lung cancer cases diagnosed worldwide [1] . Approximately two thirds of these patients have extensive disease at diagnosis [1] . Combination chemotherapy remains the cornerstone of treatment for extensive stage SCLC and improves significantly the quality of life and duration of survival [2] . Response rates in patients with extensive disease are relatively high (60%-80%) [2] ; however, virtually all patients experience relapse, and less than 5% are long-term survivors [2] .
Despite the high response rates reported with firstline regimens, results of salvage therapy for relapsing or progressing disease are poor, with infrequent objective responses and a median survival from disease progression of only two to four months [3] [4] [5] [6] . The effect of second-line chemotherapy is particularly poor in refractory patients (those failing to respond to first-line chemotherapy or experiencing early relapse), disease-free survival is virtually non-existent [4] . For patients with recurrent disease after CAV (cyclophosphamide, doxorubicin, vincristine) first-line therapy, there is some evidence that the cisplatin plus etoposide (VP-16) combination may be active as a second-line regimen [7] . However, there is no effective second-line therapy for patients relapsing after cisplatin plus VP-16 [8] . At present, the usual practice in SCLC patients with relapsing disease and a good performance status is to administer investigational chemotherapeutic agents in phase I or II trials [9] , Paclitaxel has recently shown a promising activity in SCLC. A 34% and 41% objective response rate was reported in previously untreated patients with SCLC with single-agent paclitaxel, given at a dose of 250 mg/m 2 by 24-hour infusion [10, 11] . In both studies, subsequent treatment with a platinum-etoposide regimen produced additional responses, suggesting incomplete cross-resistance between paclitaxel and this combination. In a more recent phase II study involving 24 patients with refractory disease (progression within three months), seven patients (29%) showed partial responses to paclitaxel 175 mg/m 2 given over a three-hour infusion [12] . Although the duration of response was brief in most patients (median, 108 days; range 64-243 days), these data show that paclitaxel is an active agent in SCLC since the reported response rates with other single agents or combination regimens have been less than 15% in this population of patients with refractory disease. Carboplatin has shown activity both as single agent or in combination chemotherapy regimens in previously treated SCLC patients [13, 14] . There is also evidence for synergism between paclitaxel and platinum compounds, at least//? vitro [15] .
Therefore, a multicenter phase II study with this twodrug combination was conducted in order to evaluate its toxicity profile and activity as salvage treatment in patients with refractory SCLC.
Patients and methods

Patients selection
Patients with histologically or cytologically confirmed extensive SCLC, aged < 75 years, who had failed one prior front-line chemotherapy regimen (EP, n = 27; CAV, n = 5), were enrolled. Other eligibility criteria were: performance status (WHO) 0-2; a life expectancy of at least three months; adequate haematologic parameters (absolute granulocyte count > 1500/ul, haemoglobin level >9g/dl, and platelet count > 100.000/ul), adequate hepatic (serum bilirubin <1.5 mg/dl, transaminases < twice the upper limit of normal), and renal (serum creatinine <1.5 mg/dl) function; no other medical problems severe enough to affect patient compliance to the protocol. Patients with brain metastases were eligible if they had been irradiated, the brain lesions were radiographically stable, and clinical improvement was evident. Patients with malnutrition (more than 20% loss of body weight), active infection, massive liver metastases occupying more than 50% of the liver parenchyma, or a second primary tumour other than skin squamous-cell carcinoma or in silu cervical carcinoma, were excluded from the study. All patients gave written informed consent to participate in the study and the trial was approved by the Ethical and Scientific Committees of our Institution.
Treatment schedule
Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, New Jersey) was administered at a dose of 200 mg/m 2 on day 1 by intravenous (i.v.) infusion over 3 hours after oral premedication with dexamethasone 8 mg 12 and 6 hours before paclitaxel infusion and cimetidine 300 mg i.v. push 30 min before paclitaxel infusion. Carboplatin (Paraplatin; Bristol-Myers Squibb) was given at a dose of 6 AUC (Calvert's formula) by i.v. infusion over 30 min on day 2 [16] . Treatment was administered on an outpatient basis every 4 weeks. Dose adjustment criteria were based mainly on haematological parameters. Doses of both drugs were reduced in subsequent cycles by 25% if chemotherapyinduced febrile neutropenia or grade 4 neutropenia or if thrombocytopenia lasting more than five days occurred; if the granulocyte count was less than 1500 cells/dl and/or platelet count less than 100,000 cells/dl on day 1 of any subsequent cycle the next course of chemotherapy was delayed until haematologic parameters recovered to above these levels. Following one dose-reduction due to febrile neutropenia or grade 4 neutropenia, recombinant human granulocyte colonystimulating factor (rhG-CSF) (Granocyte; Aventis) was given prophylactically at a dose of 150 ug/m 2 subcutaneously from day 7 to day 12, if needed, to avoid a second dose-reduction. A 25% dose-reduction of paclitaxel was performed in patients with grade 2 or 3 neuropathy; patients developing grade 4 neuropathy were taken off study. Dose reductions were maintained for all subsequent courses of treatment. Patients with a complete response or a partial response received three additional cycles after the criteria of response were first met while those with stable disease received a maximum of six cycles. Patients experiencing progressive disease during the treatment were withdrawn from the study.
Patient evaluation
Baseline evaluations included the following: patient history, physical examination, chest X-rays, full blood count (FBC) with differential and platelet count, blood chemistry, electrocardiograph (ECG), computed tomography (CT) scans of the chest, abdomen, and pelvis, while whole brain CT scans were performed when clinically indicated. FBCs with differential and platelet counts were performed twice weekly or daily in patients with severe myelosuppression; whole blood chemistry and physical examination were performed every four weeks. Toxicities were recorded according to WHO criteria [17] . Responses were evaluated according to WHO criteria after each cycle by physical examination or chest X-rays if appropriate; in all other patients response to treatment was assessed by computed tomography after every two chemotherapy cycles. All responses were confirmed four weeks after the first documentation of response and additional imaging studies were reviewed by an external panel of specialists.
Statistical methods
The duration of response was calculated from the day of the first demonstration of response until disease progression; the time to tumour progression (TTP) was estimated from the study entry until the documented progression of the disease, and the overall survival was measured from study entry until death. Median probability of survival and the median TTP were estimated by the method of Kaplan and Meier [18, 19] , confidence intervals for response rates were calculated using methods for exact binomial confidence intervals.
Results
From November 1997 to August 1999, 32 patients with extensive stage SCLC were enrolled onto the study. All patients had refractory disease to a previous EP or CAV front-line chemotherapy regimen and fifteen patients had been irradiated for brain or painful bone metastases. Twenty-seven patients (84.4%) were male, with a median age of 60.5 years, and twenty-nine (90.5%) had a PS 0-1 (WHO). Twenty-three patients had two or more involved sites. Patient characteristics are shown in Table 1 .
Compliance with treatment
A total of 110 chemotherapy cycles were administered and toxicity data were available from all patients and all cycles. All but three patients received more than one cycle of treatment (median number of cycles/patient = 3) and 12 (38%) patients received four or more cycles. In thirty (94%) patients the treatment was stopped after at least two cycles for the following reasons: disease progression (n -17), completion of treatment (// = 6), stable disease (n = 3) and treatment refusal because of intolerable toxicity (n = 4). Dose reductions were required in 11 treatment cycles (10%), because of grade 4 neutropenia (4 cycles), febrile neutropenia (2 cycles), grade 3 thrombocytopenia (2 cycles), and grade 2-3 asthenia (3 cycles). Ten (9%) cycles required treatment delays on day 1 because of unresolved haematologic toxicity (4 cycles) and late admissions (6 cycles). Overall, the median interval between cycles was 28 days (range 28-39). The relative dose-intensity for paclitaxel was 
Haematologic toxicity
Neutropenia was the main haematologic toxicity of the regimen. Grade 3-4 neutropenia was observed in 12 (37%) patients and 22 (20%) cycles during the whole treatment period and in 2 (6%) of them this was associated with fever. Both patients required hospitalization and were treated with G-CSF and broad spectum i.v. antibiotics. Recovery from the neutropenic episode occurred within six and four days, respectively. Neutropenia was generally of short duration with a median time to neutrophil recovery of 4 days (range 3-8). Twenty cycles required administration of rhG-CSF, either as treatment of neutropenic episodes or prophylactically. Grade 4 anaemia was observed in one (3%) patient and grade 3 thrombocytopenia in three (9%). There was no toxic death. No evidence of cumulative haematologic toxicity was seen when the median nadir counts of haemoglobin, neutrophils and platelets during cycles 1 and 3 of treatment were compared. Haematologic toxicity is summarized in (50) 4(13) 8(25) 3(9) 2(6) 3(9) -19(59) 2(6) 3(9) 2 5(16) 8(25) 4(13) 
Non-haematologic toxicity
Non-haematologic toxicity was very mild and consisted mainly of grade 1 ( Table 2) . No more than grade 1 nausea/vomiting was observed. The most common nonhaematologic toxicity was asthenia. Grade 2 or 3 asthenia was seen in two (6%) and eight (19%) patients, respectively. This toxicity was usually seen after the second treatment cycle and was the reason for dose reductions and treatment discontinuation in four and three patients, respectively. Mild hypersensitivity reactions, characterized by erythema and skin rush occurred in two (6%) patients; both patients were able to continue chemotherapy after adequate treatment with corticosteroids and antihistamines. Grade 2 fluid retention syndrome was detected in three (9%) patients and was easily manageable with oral furosemide. Non-neutropenic infections involving the lower respiratory tract occurred in two patients (6%), but were of short duration and easily manageable with standard antibiotic treatment.
Response to treatment and survival
Twenty-nine patients who had bidimensionally measurable disease and received at least two chemotherapy cycles, were evaluable for response. Two other patients refused further treatment after the first chemotherapy cycle and another one died because of disease progression; these patients were included in the response analysis as non-responders. In an intention-to-treat analysis, CR was observed in 1 patient (3%) and PR in 7 (22%) for an overall response rate of 25% (95% CI: IO%-4O%); 7 (22%) additional patients had SD and 17 (53%) PD. The median duration of response was 3 months (range 1-9), and the median time to tumour progression (TTP) 5.5 months (range 3-11.5). All but one of the responders had been previously treated with EP combination and three of them failed to respond to this front-line regimen. After a median follow-up period of 8 months (range 1-17.5), 24 patients died. The median overall survival for the entire group was 7 months (range 1-17.5) and the probability for one-year survival 15% (Figure 1 ). 
Discussion
SCLC is a chemosensitive tumour. Unfortunately, despite initial and often dramatic response to combination chemotherapy, the great majority of patients experience relapse and become candidates for second-line treatment.
The results of second-line treatment depend on several factors, such as the interval between cessation of primary therapy and relapse, the response to primary therapy, and the drugs of the front-line regimen. Indeed, responses to CAV after initial EP chemotherapy are uncommon [8, 20] . Chemosensitive tumours (response duration of at least three months) have a higher probability of responding to second-line chemotherapy while tumours relapsing within three months after front-line chemotherapy are considered as refractory to the drugs previously used. Ifosfamide, paclitaxel, topotecan and continuous oral low-dose etoposide have been tested in an effort to overcome drug-resistance in SCLC; these studies demonstrated RRs ranging from 6%-40% [12, [21] [22] [23] . However, these responses were mostly of brief duration accompanied by substantial toxicity and conferred no survival benefit [12, [21] [22] [23] . Paclitaxel has shown an interesting activity either as front-line chemotherapy or as salvage treatment in SCLC [10] [11] [12] . Carboplatin has known activity in SCLC and there is evidence for synergism between these two drugs. Therefore, this drug combination was developed in order to investigate its efficacy and tolerance in refractory SCLC patients previously treated with an EP or CAV combination.
The observed response rate of 25% in the present study is consistent with that reported for other drug combinations used as salvage treatment for refractory SCLC. It is of note, that three of the responders had not responded to the previous EP regimen indicating, at least, a lack of complete cross resistance between EP and the present drug combination. An unexpected and interesting finding in the present study was the observed seven-month median overall survival which is among the longest reported in the literature for this poor prognosis population. This favorable survival may be explained by the good performance status of the majority of the enrolled patients; however, only a randomized trial could definitely clarify whether the present drug combination could confer a survival benefit on these patients. Recently, Groen et al., reported 73% objective responses with the paclitaxel /carboplatin regimen in 35 SCLC patients rerfactory to first-line cyclophosphamide-doxorubicin-etoposide (CDE) combination [24] . However, the median survival reported was identical to the seven-month median overall survival observed in our study. The difference in response rates may be due to differences in patient characteristics (e.g., disease stage, interval between first-and second-line regimen, no of metastatic sites, etc.) and mainly because, in the Dutch study, patients had not been exposed to a platinum compound previously.
The regimen was very well tolerated with neutropenia being the main haematologic toxicity. Grade 3-4 neutropenia occurred in 37% of patients but was usually of short duration and easily manageable with rhG-CSF and standard antibiotic treatment. There were only two febrile neutropenic episodes requiring hospitalization with no septic death during the whole study period. Severe anaemia and thrombocytopenia were infrequent with only one patient experiencing grade 4 anaemia requiring packed red blood cell transfusions. As it concerned the non-haematologic toxicities, only asthenia was a treatment problem. Although it is difficult to differentiate this toxicity from the symptoms of a generalized disease such as SCLC, grade 2-3 asthenia affected eight (25%) patients and was frequently the reason for dose-reductions and treatment discontinuation. It is noteworthy that no patient developed some grade of peripheral neuropathy. This may be due to the limited median number of cycles per patient administered, and/or to the four-week interval between cycles.
In conclusion, the combination of paclitaxel and carboplatin represents a relatively active and well-tolerated regimen for salvage treatment in patients with refractory SCLC. The observed median overall survival of seven months is promising, and therefore, the regimen warrants further investigation as salvage treatment in this poor prognosis population.
